Sort   by:  
 Page size 
ProteomicsIntegrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
Clear cell renal cell carcinoma (ccRCC) is the dominant subtype of renal cancer. With currently available therapies, cure of advanced and metastatic ccRCC is achieved only in rare cases. Here, we developed a workflow integrating different -omics technologies to identify ccRCC-specific HLA-presented ...
ORGANISM(S): Homo sapiens (Human) 
2020-04-03 | PXD017149 | Pride
Peptide vaccine Ccrcc Renal cell carcinoma Ligandomics Immunotherapy Cancer vaccine Kidney cancer Hla peptidomie 
UnknownIntegrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Not available
S-EPMC7106651 | biostudies-literature
UnknownHLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
Not available
S-EPMC4910750 | biostudies-literature
UnknownPitfalls in HLA Ligandomics-How to Catch a Li(e)gand.
Not available
S-EPMC8313844 | biostudies-literature
ProteomicsImmunopeptidomics by use of a microfluidics chip.
A microfluidics technology was implemented to the immunoaffinity purification process of MHC peptides in Ligandomics/Immunopeptidomics. The thus purified HLA peptides were analysed by LCMS with the nanoElute LC and TimsTOF Pro Mass Spectrometer from Bruker. The aim of the microfluidics implementatio...
ORGANISM(S): Homo sapiens (Human) 
2022-02-17 | PXD022194 | Pride
Human Bladder cancer Ligandome Patient derived organoid Hla-i Renal cell carcinoma Microfluidics Ovarian cancer Immunopeptidome Jy cell line Chip Mhc-i Rcc 
ProteomicsImmunopeptidomics by use of a microfluidics chip.
A microfluidics technology was implemented to the immunoaffinity purification process of MHC peptides in Ligandomics/Immunopeptidomics. The thus purified HLA peptides were analysed by LCMS with the nanoElute LC and TimsTOF Pro Mass Spectrometer from Bruker. The aim of the microfluidics implementatio...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2025-07-02 | MSV000098416 | MassIVE
ProteomicsAn oncogenic SUMO program restricts the targetable cancer immunopeptidome
A balanced SUMOylation equilibrium safeguards the functional anti-tumor immune response. Oncogene activation drives SUMOylation, rendering aberrant SUMOylation a hallmark of cancer. To delineate the impact of activated SUMOylation on the tumor-immune synapse, we applied HLA class-I-targeted ligandom...
ORGANISM(S): Homo sapiens (Human) 
2026-04-06 | PXD060641 | Pride
Human Sumo Immunopeptidome Mhc-i Antigen presentation Cancer immunotherapy Phosphoproteome 
ProteomicsAberrant SUMOylation restricts the targetable cancer immunopeptidome
A balanced SUMOylation equilibrium safeguards the functional anti-tumor immune response. Oncogene activation drives SUMOylation, rendering aberrant SUMOylation a hallmark of cancer. To delineate the impact of activated SUMOylation on the tumor-immune synapse, we applied HLA class-I-targeted ligandom...
ORGANISM(S): Homo sapiens (Human) 
2026-01-25 | PXD061196 | Pride
Sumoylation Immunpeptidome 
ProteomicsThe oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKAC...
ORGANISM(S): Homo sapiens (Human) 
2022-10-13 | PXD029882 | Pride
Cancer Hla ligands Mass spectrometry Fibrolamellar hepatocellular carcinoma Immunopeptidomics Fl-hcc 
ProteomicsMapping the HLA ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation
Immunopeptidome analysis of colorectal adenocarcinoma tissues as well as adjacent benign tissues was performed to characterize the natural HLA class I and class II presented ligandome represented in the context of malignancy as well as in benign tissue of the colon.
ORGANISM(S): Homo sapiens (Human) 
2019-03-12 | PXD009602 | Pride
Neoplasia Cancer Hla-ligandomics Hla Colorectal adenocarcinoma Colon cancer Peptide Hla-restricted peptide Hla-ligand Colon 
Sort   by:  
 Page size